Sanofi/Aventis Merger Will Not Affect Exubera, Actonel Agreements – Sanofi

Sanofi-Synthelabo does not expect merging with Aventis would negatively affect Aventis' co-promotion agreements for Actonel and Exubera, CEO Jean-Francois Dehecq said during a March 11 investor call